Reappraisal of polytherapy in epilepsy: A critical review of drug load and adverse effects

Epilepsia

Volumn 38, Issue 5, 1997, Pages 570-575

  Deckers, C L P ^a   Hekster, Y A ^a   Keyser, A ^a   Meinardi, H ^a,b   Renier, W O ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE   (Netherlands)

Author keywords

Adverse effects; Antiepileptic drugs; Drug load; Epilepsy; Polytherapy

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; CLORAZEPATE; ETHOSUXIMIDE; FELBAMATE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; PROGABIDE; VALPROIC ACID; VIGABATRIN;

ADVERSE DRUG REACTION; ATTENTION; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG BLOOD LEVEL; EPILEPSY; HUMAN; MEMORY; MENTAL FUNCTION; MOTOR PERFORMANCE; NEUROPSYCHOLOGICAL TEST; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; VISUOMOTOR COORDINATION;

EID: 0030970698     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1997.tb01142.x     Document Type: Review

References (41)

1. Lammers MW, Meinardi H. On the reporting of adverse drug events. In: Meinardi H, Cramer JA, Baker GA, Martins Da Silva A, eds. Quantative assessment in epilepsy care. New York: Plenum Press, 1993:117-22.
2. Cramer JA, Smith DB, Mattson RH. A method for quantification for the evaluation of antiepileptic drug therapy. Neurology 1983;33:26-37.
3. Aldenkamp AP, Baker G, Pieters MSM, Schoemaker HC, Cohen AF, Schwabe S. The neurotoxicity scale: the validity of a patient-based scale, assessing neurotoxicity. Epilepsy Res 1995;20:229-39.
4. Shorvon SD, Reynolds EH. Unnecessary polypharmacy for epilepsy. Br Med J 1977;1:1635-7.
5. Shorvon SD, Reynolds EH. Reduction in polypharmacy for epilepsy. Br Med J 1979;2:1023-5.
6. Milan Collaborative Group for Studies on Epilepsy. Long-term intensive monitoring in the difficult patient. Preliminary results of 16 months of observations - usefulness and limitations. In: Gardner-Thorpe C, Janz D, Meinardi H, Pippenger CE, eds. Antiepileptic drug monitoring, 1st ed. Tunbridge Wells, Kent, England: Pitman Medical Publishing, 1977:197-213.
7. Reynolds EH, Shorvon SD. Monotherapy or polytherapy for epilepsy? Epilepsia 1981;22:1-10.
8. Thompson PJ, Trimble MR. Anticonvulsant serum levels: relationship to impairments of cognitive functioning. J Neurol Neurosurg Psychiatry 1983;46:227-33.
9. Lammers MW, Hekster YA, Keyser A, Meinardi H, Renier WO, Lier H van. Monotherapy or polytherapy for epilepsy revisited: a quantitative assessment. Epilepsia 1995;36:440-6.
10. Pippenger CE. Rationale and clinical application of therapeutic drug monitoring. Pediatr Clin North Am 1980;27:891-925.
11. Eadie MJ. Anticonvulsant drugs. An update. Drugs 1984;27:328-63.
12. Meijer JWA. Knowledge, attitude and practice in antiepileptic drug monitoring. Acta Neurol Scand 1991;83(suppl 134):1-128.
13. Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs, 4th ed. New York: Raven Press, 1995.
14. Matsuo F, Bergen D, Faught E, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. US Lamotrigine Protocol 0.5 Clinical Trial Group. Neurology 1993;43:2284-91.
15. Anhut H, Ashman P, Feuerstein TJ, Sauermann W, Saunders M, Schmidt B. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. The International Gabapentin Study Group. Epilepsia 1994;35:795-801.
16. Handforth A, Treiman DM. Efficacy and tolerance of long-term, high-dose gabapentin: additional observations. Epilepsia 1994;35:1032-7.
17. Ludgate J, Keating J, O'Dwyer R, Callaghan N. An improvement in cognitive function following polypharmacy reduction in a group of epileptic patients. Acta Neurol Scand 1985;71:448-52.
18. Ring HA, Heller AJ, Farr IN, Reynolds EH. Vigabatrin: rational treatment for chronic epilepsy. J Neurol Neurosurg Psychiatry 1990;53:1051-5.
19. Kuzniecky R, Rubin ZK, Faught E, Morawetz R. Antiepileptic drug treatment after temporal lobe epilepsy surgery: a randomized study comparing carbamazepine and polytherapy. Epilepsia 1992;33:908-12.
20. Albright P, Bruni J. Reduction of polypharmacy in epileptic patients. Arch Neurol 1985;42:797-9.
21. Schmidt D. Two anti-epileptic drugs for intractable epilepsy with complex-partial seizures. J Neurol Neurosurg Psychiatry 1982;45:1119-24.
22. Treiman DM, Pledger GW, DeGiorgio C, Tsay J-Y, Cereghino JJ. Increasing plasma concentrations tolerability study of flunarizine in comedicated epileptic patients. Epilepsia 1993;34:944-53.
23. Wagner ML, Graves NM, Marienau K, Holmes GB, Remmel RP, Leppik IE. Discontinuation of phenytoin and carbamazepine in patients receiving felbamate. Epilepsia 1991;32:398-406.
24. Monaco F, Riccio A, Benna P, et al. Further observations on carbamazepine plasma levels in epileptic patients. Relationships with therapeutic and side effects. Neurology 1976;26:936-73.
25. Loiseau P, Bossi L, Guyot M, Orofiamma B, Morselli PL. Double-blind crossover trial of progabide versus placebo in severe epilepsies. Epilepsia 1983;24:703-15.
26. Schmidt D. Progabide as an add-on drug for epilepsy refractory to high dose antiepileptic drug therapy. Neurosci Lett 1984;47:357-60.
27. Schmidt D. Reduction of two-drug therapy in intractable epilepsy. Epilepsia 1983;24:368-76.
28. Loiseau P, Hardenberg JP, Pestre M, Guyot M, Scheeter PJ, Tell GP. Double-blind, placebo-controlled study of vigabatrin in drug-resistant epilepsy. Epilepsia 1986;27:115-20.
29. Loiseau P, Yuen AW, Duche B, Menager T, Arne-Bes MC. A randomised double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures. Epilepsy Res 1990;7:136-45.
30. Tartara A, Manni R, Galimberti CA, Hardenberg J, Orwin J, Perucca E. Vigabatrin in the treatment of epilepsy: a double-blind placebo-controlled study. Epilepsia 1986;27:717-23.
31. Sander JW, Patsalos PN, Oxley JR, Hamilton MJ, Yuen WC. A randomised double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy. Epilepsy Res 1990;6:221-6.
32. Leppik IE, Dreifuss FE, Pledger GW, et al. Felbamate for partial seizures: results of a controlled clinical trial. Neurology 1991;41:1785-9.
33. Wilensky AJ, Moretti-Ojeman L, Temkin NR, Troupin AS, Dodrill CB. Clorazepate and phenobarbital as antiepileptic drugs: a double-blind study. Neurology 1981;31:1271-6.
34. Duncan JS, Shorvon SD, Trimble MR. Effects of removal of phenytoin, carbamazepine, and valproate on cognitive function. Epilepsia 1990;31:584-91.
35. McGuire A, Duncan JS, Trimble RM. Effects of vigabatrin on cognitive function and mood when used as add-on therapy in patients with intractable epilepsy. Epilepsia 1992;33:128-34.
36. Fenickle RR, Lipicky RJ. Combination products as first-line pharmacotherapy. Arch Intern Med 1994;154:1429-30.
37. Frishman WH, Bryzinski BS, Coulson LR, et al. A multifactorial trial design to assess combination therapy in hypertension. Arch Intern Med 1994;154:1461-8.
38. Dorie MJ, Brown JM. Tumor-specific schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 1993;53:4633-6.
39. Loiseau P, Strube E, Broustet D, Battelochi S, Gomeni C, Morselli PL. Learning impairment in epileptic patients. Epilepsia 1983;24:183-92.
40. Aldenkamp AP, Alpherts WC, Diepman L, et al. Cognitive side effects of phenytoin compared with carbamazepine in patients with localization-related epilepsy. Epilepsy Res 1994;19:37-43.
41. Smith DB, Goldstein SG, Roomet A. A comparison of the toxicity of the anticonvulsant eterobarb (Antilon, DMMP) and phenobarbital in normal human volunteers. Epilepsia 1986;18:149-55.